Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia after Treatment with Recombinant Erythropoietin Products: Recommendations for Minimization of Risk
نویسندگان
چکیده
منابع مشابه
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
Since 1998, there has been a marked increase in incidence of pure red cell aplasia secondary to development of anti-erythropoietin antibodies (Ab+ PRCA) in patients who have chronic kidney disease (CKD) and receive recombinant erythropoietin. The relationship between incidence of Ab+ PRCA and specific erythropoietin products has not been examined rigorously. Manufacturers provided data regardin...
متن کاملAnti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation
Patients undergoing antiviral therapy for chronic hepatitis C often develop anemia secondary to ribavirin and interferon. Recombinant erythropoietin has been used to improve anemia associated with antiviral therapy and to minimize dose reductions, which are associated with decreased rates of sustained virologic response. A rare potential side effect of recombinant erythropoietin is anti-erythro...
متن کاملIncidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)
BACKGROUND Subcutaneous administration of Eprex(®) (epoetin alfa) in patients with chronic kidney disease (CKD) was contraindicated in the European Union between 2002 and 2006 after increased reports of anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA). The Prospective Immunogenicity Surveillance Registry (PRIMS) was conducted to estimate the incidence of antibody-mediated PRCA...
متن کاملPure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.
Recombinant human erythropoietin (epoetin) was first used for the treatment of renal anaemia in 1986. During the first 10 years of its use, epoetin-induced antibodies were a rare complication and only three cases of patients with epoetin-induced antibodies associated with pure red cell aplasia (PRCA) were published. Since 1998, however, there has been a significant increase in the number of pat...
متن کاملPure Red Cell Aplasia Induced by Antibodies against Human Recombinant Erythropoietin
Human recombinant erythropoietin (epoetin) is a very effective and safe biopharmaceutical. However, in 1998 the incidence of pure red cell aplasia (PRCA) induced by antierythropoietin (anti-EPO) antibodies in patients treated with epoetin started to increase. PRCA is a rare condition of non-regenerative anemia which can be associated with a variety of diseases and is in some cases of immunologi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Society of Nephrology
سال: 2004
ISSN: 1046-6673,1533-3450
DOI: 10.1097/01.asn.0000140219.28618.9f